(c) 2024 PillSync.com

Carbidopa 25 MG Levodopa 100 MG Extended Release Oral Tablet

INDICATIONS AND USAGE Carbidopa and levodopa extended-release tablets are indicated in the treatment of Parkinson's disease, post-encephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide intoxication or manganese intoxication.

american health packaging


4 years ago OVAL ORANGE 461 Carbidopa 25 MG  Levodopa 100 MG Extended Release Oral Tablet

OVAL ORANGE 461

4 years ago OVAL ORANGE 461 Carbidopa 25 MG  Levodopa 100 MG Extended Release Oral Tablet

461 OVAL ORANGE

HOW SUPPLIED

CARBIDOPA AND LEVODOPA extended-release tablets 50 mg/200 mg containing 50 mg of carbidopa and 200 mg of levodopa, are buff colored, oval, biconvex uncoated tablets debossed “457” on one side and scored on other side, with mottled appearance. They are supplied as follows: Unit dose packages of 100 (10 x 10) NDC 68084-282-01

CARBIDOPA AND LEVODOPA extended-release tablets 25 mg/100 mg containing 25 mg carbidopa and 100 mg of levodopa, are buff colored, oval, biconvex, uncoated tablets debossed “461” on one side and plain on other side, with mottled appearance. They are supplied as follows: Unit dose packages of 100 (10 x 10) NDC 68084-281-01 Storage Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). [See USP Controlled Room Temperature]. Store in a tightly closed container. Protected from light and moisture. FOR YOUR PROTECTION: Do not use if blister is torn or broken.


More pills like OVAL 461












DISCLAIMER:

"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."

"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."

"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."

PillSync may earn a commission via links on our site